Pedro Romero Selected Research

Antigens

09/2008	Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.
03/2008	Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.
02/2006	Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
01/2006	The human T cell response to melanoma antigens.
01/2006	Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
03/2004	Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.
01/2004	gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
12/2003	Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
10/2003	Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
09/2003	Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
05/2003	Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
02/2003	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
11/2002	Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
07/2002	Functional analysis of HLA-A0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A0201- donor: exploring tumor antigen allorestricted recognition.
05/2002	Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen.
03/2002	In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
02/2002	CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
02/2002	Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.

Articles by Research Topic

Disease

24	Neoplasms (Cancer) 09/2008 - 02/2002
18	Melanoma (Melanoma, Malignant) 05/2008 - 02/2002
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2007 - 10/2006
1	Colorectal Neoplasms (Colorectal Cancer) 11/2007
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/2007
1	Endophthalmitis (Ophthalmia) 03/2006
1	Cataract (Cataracts) 03/2006
1	Testicular Neoplasms (Testicular Cancer) 02/2006

Drug/Important Bio-Agent (IBA)

18	AntigensIBA 09/2008 - 02/2002
3	PeptidesIBA 11/2004 - 10/2002
3	Peptide LibraryIBA 11/2002 - 04/2002
2	EpitopesIBA 11/2006 - 10/2003
2	HLA-A*0201 antigenIBA 11/2004 - 07/2002
2	LigandsIBA 08/2002 - 04/2002
1	methionyltryptophanIBA 09/2008
1	Interleukin-2 (IL2)IBA 05/2008
1	CAP1-6DIBA 12/2007
1	Carcinoembryonic AntigenIBA 11/2007
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 11/2007
1	Toll-Like Receptor 3IBA 08/2007
1	Retinaldehyde (Retinal)IBA 03/2007
1	fludarabineIBA 02/2007
1	Busulfan (Busulfex)FDA Link 02/2007
1	Cefazolin (Ancef)FDA LinkGeneric 03/2006
1	L-SelectinIBA 02/2004
1	VaccinesIBA 12/2003
1	telomerase reverse transcriptase (540-548)IBA 10/2002
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 08/2002
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 08/2002
1	Subunit VaccinesIBA 03/2002
1	Proteasome Endopeptidase Complex (Proteasome)IBA 02/2002

Therapy/Procedure

4	Immunotherapy 01/2008 - 01/2005
1	Drug Therapy (Chemotherapy) 01/2008